ProPhase Labs, Inc. Overview
Pro stress-test →ProPhase Labs develops and commercializes novel drugs, dietary supplements, and compounds in the United States through two segments: Diagnostic Services and Consumer Products. The company is revolutionizing healthcare with whole genome sequencing solutions, diagnostic development including a test for early detection of esophageal cancer, and direct-to-consumer marketing of cutting-edge OTC dietary supplements.
Strategic Profile
Pro stress-test →ProPhase focuses on three primary areas: molecular diagnostics and precision oncology including the BE-Smart Esophageal Cancer Test, genomics through Nebula Genomics, and consumer health via OTC dietary supplements. In December 2025, ProPhase announced a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S.A., though the transaction is preliminary and subject to due diligence and regulatory approvals.
Competitive Landscape
Pro stress-test →ProPhase competes in genomic testing and diagnostic screening with products like BE-Smart for esophageal cancer detection and DNA Expand platform. The company operates in multiple adjacent markets including consumer supplements (competing with established OTC brands) and diagnostic services (competing with larger diagnostic labs and genomics companies).
Industry Context
ProPhase Labs, Inc. operates in Biotechnology, Pharmaceutical Manufacturing & Diagnostics.
Key facts
Founded: 1933 (as The Quigley Corporation) · Headquarters: Uniondale, NY · Market cap: $16.74M